1. Search Result
Search Result
Results for "

EF

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

7

Peptides

5

Natural
Products

10

Recombinant Proteins

1

Isotope-Labeled Compounds

9

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-U00118

    Others Cancer
    EF-5 (EF5; 2-Nitroimidazole) is a hypoxia labeling agent used to identify hypoxia in cells.
    EF-5
  • HY-119272
    EF24
    1 Publications Verification

    ERK Caspase Cancer
    EF24 is a curcumin analogue with greater anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 treatment increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK .
    EF24
  • HY-B0750B

    MDL-73147EF hydrate

    5-HT Receptor Others
    Dolasetron Mesylate hydrate (MDL-73147EF hydrate) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.
    Dolasetron Mesylate hydrate
  • HY-P1075
    CALP3
    2 Publications Verification

    Calcium Channel Neurological Disease Cancer
    CALP3, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .
    CALP3
  • HY-118931

    Others Neurological Disease
    EF-1502 is a potent and selective GABA transporter inhibitor with GAT1 and BGT1 inhibitory activity. EF-1502 produces a synergistic anti-epileptic effect when used in combination with Tiagabine (HY-B0696), a compound used to suppress epileptic seizures. The dosing combination of EF-1502 exhibited reduced anti-epileptic efficacy and dyskinesia when used with THIP (HY-10232). The mechanism of EF-1502 differs significantly from Tiagabine, suggesting a unique role in the inhibitory strategy .
    EF-1502
  • HY-161690

    CDK Others
    EF-4-177 is an orally active and allosteric CDK2 inhibitor with the IC50 of 87 nM. EF-4-177 can disrupt spermatogenesis .
    EF-4-177
  • HY-B0750A

    MDL-73147EF

    5-HT Receptor Cancer
    Dolasetron Mesylate (MDL-73147EF) is a serotonin 5-HT3 receptor antagonist used to treat nausea and vomiting following chemotherapy.
    Dolasetron Mesylate
  • HY-P1075A

    Calcium Channel Neurological Disease Cancer
    CALP3 TFA, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .
    CALP3 TFA
  • HY-122386

    Mocimycin; Delvomycin

    Bacterial Antibiotic Infection
    Kirromycin (Mocimycin) is an antibiotic produced by Streptomyces collinus Tu 365. Kirromycin is a bacterial protein synthesis inhibitor that immobilizes elongation factor Tu (EF-Tu) on the elongating ribosome .
    Kirromycin
  • HY-P10396

    Bacterial Infection Inflammation/Immunology
    Elf18 is the bacterial N-terminal fragment of Elongation Factor Thermus (EF-Tu). Elf18 is recognized by pattern recognition receptors (PRRs) as a pathogen-associated molecular pattern (PAMP), and thus induces immune response in Arabidopsis .
    Elf18
  • HY-B1350
    Fusidic acid
    2 Publications Verification

    Fusidate; SQ-16603

    Bacterial Antibiotic Infection Cancer
    Fusidic acid (Fusidate) a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid has no corticosteroid effects. Fusidic acid inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome .
    Fusidic acid
  • HY-B1350S

    Fusidate-d6; SQ-16603-d6

    Bacterial Antibiotic Infection
    Fusidic acid-d6 is the deuterium labeled Fusidic acid. Fusidic acid (Fusidate) a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid has no corticosteroid effects. Fusidic acid inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome[1][2].
    Fusidic acid-d6
  • HY-B1350R

    Fusidate (Standard); SQ-16603 (Standard)

    Antibiotic Bacterial Cancer
    Fusidic acid (Standard) is the analytical standard of Fusidic acid. This product is intended for research and analytical applications. Fusidic acid (Fusidate) a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid has no corticosteroid effects. Fusidic acid inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome .
    Fusidic acid (Standard)
  • HY-B1350AR

    Bacterial Antibiotic Infection Cancer
    Fusidic acid (sodium salt) (Standard) is the analytical standard of Fusidic acid (sodium salt). This product is intended for research and analytical applications. Fusidic acid sodium salt (Sodium fusidate), a bacteriostatic antibiotic produced from the Fusidium coccineum fungus, belongs to the class of steroids. Fusidic acid sodium salt has no corticosteroid effects. Fusidic acid sodium salt inhibits the growth of bacteria by preventing the release of translation elongation factor G (EF-G) from the ribosome .
    Fusidic acid sodium salt (Standard)
  • HY-P1076

    Calmodulin Inflammation/Immunology
    CALP2 is a calmodulin (CaM) antagonist ( (Kd of 7.9 µM)) with high affinity for binding to the CaM EF-hand/Ca 2+-binding site. CALP2 inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca 2+ concentrations. CALP2 potently inhibits of adhesion and degranulation. CALP2 is also a strong activator of alveolar macrophages .
    CALP2
  • HY-118207

    GABA Receptor Cancer
    LU-32-176B, a GABA transporter 1(GAT1) selective inhibitor, is found to exert a synergistic anticonvulsant action with GAT2 transport inhibitor EF1502. LU-32-176B inhibits neurons, astrocytes and mGAT1 with the IC50 values of 2μM, 1μM, 4μM, respectively .
    LU-32-176B
  • HY-P1076A

    Calmodulin Inflammation/Immunology
    CALP2 TFA is a calmodulin (CaM) antagonist (Kd of 7.9 µM) with high affinity for binding to the CaM EF-hand/Ca 2+-binding site. CALP2 TFA inhibits CaM-dependent phosphodiesterase activity and increases intracellular Ca 2+ concentrations. CALP2 TFA potently inhibits of adhesion and degranulation. CALP2 TFA is also a strong activator of alveolar macrophages .
    CALP2 TFA
  • HY-P1077

    mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin Inflammation/Immunology
    CALP1 is a calmodulin (CaM) agonist (Kd of 88 µM) with binding to the CaM EF-hand/Ca 2+-binding site. CALP1 blocks calcium influx and apoptosis (IC50 of 44.78 µM) through inhibition of calcium channel opening. CALP1 blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 activates CaM-dependent phosphodiesterase activity .
    CALP1
  • HY-148043

    Others Others
    Schnurri-3 inhibitor-1 is a potent schnurri-3 inhibitor which is an essential regulator of adult bone formation. Schnurri-3 inhibitor-1 can inhibit Shn3 with EF1alpha promoter in osteoblast cell line Shn3FFL with an AC50 value of 2.09 μM. Schnurri-3 inhibitor-1 can be used to research osteoporosis .
    Schnurri-3 inhibitor-1
  • HY-P1077A
    CALP1 TFA
    1 Publications Verification

    mGluR Phosphodiesterase (PDE) Apoptosis Calmodulin Inflammation/Immunology
    CALP1 TFA is a calmodulin (CaM) agonist (Kd of 88 µM) with binding to the CaM EF-hand/Ca 2+-binding site. CALP1 TFA blocks calcium influx and apoptosis (IC50 of 44.78 µM) through inhibition of calcium channel opening. CALP1 TFA blocks glutamate receptor channels and blocks a store-operated nonselective cation channel. CALP1 TFA activates CaM-dependent phosphodiesterase activity .
    CALP1 TFA
  • HY-B1350A
    Fusidic acid sodium salt
    2 Publications Verification

    Sodium fusidate; SQ-16360

    Bacterial Antibiotic Interleukin Related Infection Inflammation/Immunology
    Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice .
    Fusidic acid sodium salt

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: